证券代码：603363 证券简称：傲农生物 公告编号：2025-100 （一）审议通过《公司 2025 年第三季度报告》 表决结果：同意票 9 票、反对票 0 票、弃权票 0 票。 本议案已经第四届董事会审计委员会第十四次会议审议通过。 具体内容详见公司同日于上海证券交易所网站（www.sse.com.cn）披露的《公 司 2025 年第三季度报告》。 （二）审议通过《关于设立福建傲农在线网络科技等全资子公司暨构建福 建省餐饮生鲜猪、牛、羊肉供应链体系的议案》 福建傲农生物科技集团股份有限公司 第四届董事会第十九次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 福建傲农生物科技集团股份有限公司（以下简称"公司"）第四届董事会第 十九次会议于 2025 年 10 月 27 日在公司会议室以现场会议与通讯会议相结合的 方式召开，会议通知和材料已于 2025 年 10 月 24 日以专人送达、电子邮件、短 信或即时通讯工具等方式发出。本次会议由董事长苏明城先生召集和主持，会议 应出席董事 9 人 ...

Financial Performance - The company's operating revenue for the third quarter reached ¥2,378,228,038.62, representing a year-on-year increase of 4.79%[4] - The total profit for the year-to-date period was ¥411,906,851.31, showing a year-on-year decrease of 8.52%[4] - The net profit attributable to shareholders for the third quarter was ¥53,132,187.70, while the year-to-date net profit was ¥413,933,328.13[4] - Total operating revenue for the first three quarters of 2025 was CNY 6,335,161,290.25, a decrease of 8.5% compared to CNY 6,925,141,428.12 in the same period of 2024[18] - Net profit for the first three quarters of 2025 was CNY 439,170,633.46, a significant recovery from a net loss of CNY 953,197,224.77 in the same period of 2024[19] - The company reported an operating profit of CNY 400,203,260.86 for the first three quarters of 2025, compared to an operating loss of CNY 842,841,306.91 in the previous year[19] - Basic earnings per share for the first three quarters of 2025 were CNY 0.16, compared to a loss of CNY 0.94 in the same period of 2024[20] Cash Flow and Assets - The cash flow from operating activities for the year-to-date period was negative at -¥291,468,594.15, a decrease of 287.60% compared to the previous year[5] - The company's cash and cash equivalents were reported at CNY 696.90 million, down from CNY 1.38 billion, indicating a significant decrease of approximately 49.6%[14] - The company's total current assets amounted to approximately CNY 3.52 billion, a decrease from CNY 3.70 billion as of December 31, 2024, representing a decline of about 4.8%[14] - Cash inflow from operating activities totaled $6,183,352,836.02, a decrease of 15.7% compared to $7,334,289,947.79 in the previous period[23] - Net cash outflow from operating activities was $291,468,594.15, contrasting with a net inflow of $155,362,935.60 previously[23] - The ending cash and cash equivalents balance was $353,065,577.53, slightly up from $335,867,519.81 at the end of the previous period[24] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥9,148,144,968.13, a decrease of 3.77% from the end of the previous year[5] - The total assets decreased to CNY 9,148,144,968.13 from CNY 9,506,097,034.21 year-over-year[16] - Total liabilities decreased to CNY 5,362,979,574.42 from CNY 6,444,948,812.96 year-over-year[16] - The company's fixed assets were valued at CNY 3.17 billion, down from CNY 3.40 billion, indicating a decrease of about 6.8%[14] - Long-term equity investments slightly decreased to CNY 121.56 million from CNY 125.55 million, a decline of approximately 3.2%[14] - The company’s long-term borrowings increased to CNY 1,586,852,473.04 from CNY 1,462,234,553.47 year-over-year[16] - The company’s total equity increased to CNY 3,785,165,393.71 from CNY 3,061,148,221.25 year-over-year[16] Shareholder Structure - The company has a significant shareholder structure with the top 10 shareholders holding a total of 1,267,995,301 shares, indicating a concentrated ownership[12] - The company has established consistent action relationships among several major shareholders, which may influence future strategic decisions[12] Non-Recurring Items and Restructuring - Non-recurring gains and losses for the current period totaled ¥84,415,557.50, with significant contributions from debt restructuring gains[7] - The company has undergone bankruptcy restructuring, which has alleviated operational burdens and reduced interest expenses significantly[8] - The increase in equity is attributed to the net profit growth and capital reserve increase from debt restructuring[8] Inventory and Receivables - Accounts receivable increased to CNY 706.78 million, compared to CNY 393.06 million in the previous period, reflecting an increase of about 79.9%[14] - Inventory levels rose to CNY 887.77 million, up from CNY 816.94 million, marking an increase of approximately 8.7%[14] - The company reported a total of CNY 898.31 million in other receivables, an increase from CNY 739.10 million, representing an increase of about 21.5%[14] - The company's production biological assets increased to CNY 318.67 million, compared to CNY 213.46 million, reflecting a growth of approximately 49.3%[14] Cash Flow from Investing and Financing Activities - Cash outflow from investing activities amounted to $198,360,042.39, down from $236,521,582.13, resulting in a net cash outflow of $133,607,659.96 from investing activities[24] - Total cash inflow from financing activities was $302,194,811.68, significantly lower than $835,829,180.76 in the prior period[24] - Net cash outflow from financing activities reached $353,526,276.38, compared to a net inflow of $50,378,894.08 previously[24] - The company reported a significant increase in cash received from the disposal of fixed assets, totaling $2,561,701.70 compared to $151,529,710.59 previously[23] - Cash received from investment activities was $64,752,382.43, a decrease from $214,636,632.20 in the previous period[23] - The company experienced a decrease in cash received from the absorption of investments, totaling $18,044,320.00 compared to $33,054,700.00 previously[24] Accounting Standards - The company will not apply new accounting standards starting from 2025[25]

Market Overview - The feed sector increased by 1.16% on October 27, with Jin Xin Nong leading the gains [1] - The Shanghai Composite Index closed at 3996.94, up 1.18%, while the Shenzhen Component Index closed at 13489.4, up 1.51% [1] Individual Stock Performance - Jin Xin Nong (002548) closed at 4.80, up 5.49% with a trading volume of 369,000 shares and a turnover of 173 million yuan [1] - Tian Kang Biological (002100) closed at 7.89, up 5.34% with a trading volume of 506,600 shares [1] - Tian Ma Technology (603668) closed at 14.06, up 4.15% with a trading volume of 218,000 shares and a turnover of 302 million yuan [1] - Ao Nong Biological (603363) closed at 5.16, up 4.03% with a trading volume of 1,878,500 shares and a turnover of 451 million yuan [1] - Other notable stocks include Bangtai Technology (603151) at 26.26, up 1.70%, and Hai Da Group (002311) at 58.18, up 0.97% [1] Capital Flow Analysis - The feed sector saw a net inflow of 132 million yuan from institutional investors, while retail investors experienced a net outflow of 148 million yuan [2] - The main capital inflow and outflow for key stocks are as follows: - Ao Nong Biological: Net outflow of 40.5 million yuan from main capital [3] - Tian Ma Technology: Net inflow of 34.8 million yuan from main capital [3] - Tian Kang Biological: Net inflow of 32.8 million yuan from main capital [3] - Hai Da Group: Net inflow of 30.4 million yuan from main capital [3]

Core Insights - The feed sector experienced a slight decline of 0.17% on October 24, with Tianma Technology leading the losses [1] - The Shanghai Composite Index closed at 3950.31, up 0.71%, while the Shenzhen Component Index closed at 13289.18, up 2.02% [1] Feed Sector Performance - Zhongchong Co., Ltd. (002891) saw a closing price of 54.36, with an increase of 3.74% and a trading volume of 96,700 shares, amounting to a transaction value of 526 million yuan [1] - Other notable performers included Boen Group (001366) with a closing price of 13.03, up 0.77%, and Petty Co., Ltd. (300673) at 17.42, up 0.40% [1] - Tianma Technology (603668) led the declines with a closing price of 13.50, down 4.66%, and a trading volume of 222,500 shares, resulting in a transaction value of 309 million yuan [2] Capital Flow Analysis - The feed sector experienced a net outflow of 154 million yuan from institutional investors, while retail investors saw a net inflow of 97.74 million yuan [2] - The capital flow for individual stocks showed that Zhongchong Co., Ltd. had a net inflow of 12.28 million yuan from institutional investors, while it faced a net outflow of 36.39 million yuan from retail investors [3] - Other stocks like He Feng Co., Ltd. (60360a) and Boen Group (001366) also showed mixed capital flows, with varying degrees of net inflows and outflows from different investor categories [3]

Core Points - The stock price of Aonong Biological dropped by 2.17% on October 21, trading at 4.96 CNY per share with a total market capitalization of 12.911 billion CNY [1] - Aonong Biological's stock has increased by 40.11% year-to-date, but has seen a decline of 7.98% over the last five trading days and 17.88% over the last twenty days [1] - The company has been listed on the "Dragon and Tiger List" twice this year, with the most recent net purchase of 14.9985 million CNY on August 27 [1] Company Overview - Aonong Biological, established on April 26, 2011, and listed on September 26, 2017, is located in Zhangzhou, Fujian Province [1] - The company's main business segments include feed (66.22%), breeding (20.95%), food (12.60%), and other (0.22%) [1] - As of June 30, the number of shareholders increased by 17.87% to 46,000, while the average circulating shares per person decreased by 7.64% to 34,720 shares [2] Financial Performance - For the first half of 2025, Aonong Biological reported a revenue of 3.957 billion CNY, a year-on-year decrease of 15.01%, while net profit attributable to shareholders increased by 166.81% to 361 million CNY [2] - The company has distributed a total of 180 million CNY in dividends since its A-share listing, with no dividends paid in the last three years [3]

Core Insights - The feed sector experienced a decline of 0.32% on October 17, with Aonong Biological leading the drop [1] - The Shanghai Composite Index closed at 3839.76, down 1.95%, while the Shenzhen Component Index closed at 12688.94, down 3.04% [1] Market Performance - Key stocks in the feed sector showed varied performance, with TianKang Biological up by 1.43% to 7.78, while Aonong Biological fell by 5.60% to 5.06 [1][2] - The trading volume for TianKang Biological was 576,900 shares, with a transaction value of 449 million yuan [1] - Aonong Biological had a trading volume of 852,600 shares, with a transaction value of 442 million yuan [2] Capital Flow - The feed sector saw a net outflow of 174 million yuan from institutional investors, while retail investors had a net inflow of 101 million yuan [2] - The table of capital flow indicates that TianKang Biological had a net outflow of 14.47 million yuan from institutional investors, but a net inflow of 34.57 million yuan from retail investors [3] - Aonong Biological experienced a significant net outflow of 7.17 million yuan from institutional investors [3]

Summary of Key Points Core Viewpoint - Multiple shareholders across various companies are planning to reduce their stakes, indicating potential shifts in ownership and market dynamics [1] Shareholder Reductions - Xiaoming Co., Ltd. shareholders Xiamen Chentu and its concerted parties plan to reduce their holdings by up to 2.97% [1] - Zhongdian Port shareholders Zhongdian Kunrun Fund and Zhongdian Development Fund intend to reduce their stakes by up to 1% [1] - Liao Ning Zhongde, Huzhou Yuntong, and Haitong Innovation, shareholders of Canxin Co., Ltd., plan to collectively reduce their holdings by no more than 324,790 shares [1] - Former controlling shareholder of Hangxin Technology, Liu Shaojian, plans to reduce his stake by up to 0.98% [1] - The actual controller of Jingda Co., Ltd., Li Guangrong, intends to reduce his holdings by no more than 3% [1] - Shareholders Wu Youcai and Guo Qinghui of Aonong Biological plan to collectively reduce their holdings by up to 894,000 shares [1] - Shareholders Shanghai Yundun and Shanghai Lanxiao of Action Education plan to collectively reduce their holdings by up to 2.3 million shares [1] - Shareholder Tong Yi Furong No. 16 of Yinlong Co., Ltd. plans to reduce their stake by up to 1.96% [1] - Donghua Software's director and general manager, Lv Bo, plans to reduce his holdings by no more than 1.519 million shares [1] Other Notable Events - Xin Sai Co., Ltd. announced that Xin Sai Trading has been declared bankrupt by the court [1] - Jinjia Co., Ltd. reported that 37.27 million shares held by Jinjia Chuangtou are subject to judicial auction [1]

Group 1 - The major shareholders of Fujian Aonong Biological Technology Group Co., Ltd. hold a total of 336,270,547 shares, accounting for 12.9188% of the company's total equity [2] - Wu Youcai plans to reduce his holdings by up to 794,007 shares (0.0305% of total equity), while Guo Qinghui plans to reduce his holdings by up to 100,050 shares (0.0038% of total equity) [3] - The reduction period will commence 15 trading days after the announcement and will last for three months [3] Group 2 - The shareholders have made commitments regarding their shareholding, including a lock-up period of 36 months post-IPO for Wu Youcai [5] - The planned reduction is consistent with previously disclosed commitments [6] - The company will continue to monitor the progress of the reduction plan and fulfill its information disclosure obligations [7]

智通财经APP讯，傲农生物(603363.SH)发布公告，为满足自身资金需求，吴有材先生计划通过集中竞 价或大宗交易方式减持本公司股份不超过79.4万股(即不超过公司总股本的0.0305%)，郭庆辉先生计划通 过集中竞价减持公司股份不超过10.01万股(即不超过公司总股本的0.0038%)，减持期间为减持计划公告 披露之日起15个交易日后的3个月内。 ...

Core Viewpoint - Aonong Biological (603363.SH) announced plans for share reduction by key executives to meet funding needs [1] Group 1: Share Reduction Plans - Mr. Wu Youcai plans to reduce his holdings by up to 794,000 shares, representing no more than 0.0305% of the company's total share capital [1] - Mr. Guo Qinghui intends to reduce his holdings by up to 100,100 shares, accounting for no more than 0.0038% of the company's total share capital [1] - The reduction period will commence 15 trading days after the announcement and will last for three months [1]